Inclusion Criteria:

- B-CLL

- Age >18

- ECOG performance status 0-2

- Previous Rituximab containing induction treatment of the CLL in 1st or 2nd line

- Patient must be in complete remission or partial remission after an induction
treatment containing rituximab

- ANC (absolute neutrophil count) > 1,0 x 10e9 /L

- Life expectancy > 6 months

- Patient´s written informed consent

- Patient using a reliable means of contraception for the duration of the treatment
including 2 months thereafter

Exclusion Criteria:

- Active uncontrolled bacterial, viral or fungal infection

- Significantly reduced organ functions and bone marrow dysfunction not due to CLL

- creatinine clearance of below 30mL/min

- Patients with a history of other malignancies within 2 years prior to study entry

- Patients with a history of severe cardiac disease

- Other known comorbidity with the potential to dominate survival

- Transformation to aggressive B-cell malignancy

- Hypersensitivity with anaphylactic reaction to humanized monoclonal antibodies or any
of the applied drugs

- Medical condition requiring prolonged (> 1 month) use of oral corticosteroids

- Pregnant or breast feeding women

- Any coexisting medical or psychological condition that would preclude participation
in the study or compromise ability to give informed consent